Harlan Contract Research Services Cytotest Cell Research Selected for Membership in EU-NETVAL
News Aug 12, 2013
EU-NETVAL provides support for the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.
“Being in the initial group of laboratories acknowledges the expertise of our scientists as well as our continuous work in and support for alternative in vitro methodologies, including our participation in EU validation projects in the past,” said Dr. Albrecht Poth, deputy managing director and scientific advisor for Harlan CRS Cytotest Cell Research. “We are honored to have Harlan CRS play a role in this important research evolution.”
The aim of EURL ECVAM is to promote the scientific and regulatory acceptance of non-animal tests and to coordinate the independent evaluation of tests for specific purposes. Harlan CRS Cytotest Cell Research will contribute to the development of guidance documents, procedures, training materials and collaboration tools that facilitate the development, validation and acceptance of alternative methods.
Harlan CRS began as a regional provider of research models and services in the Midwestern U.S. more than 70 years ago and today is a global provider of those services.
“We have been researching new test systems in the fields of alternative toxicology, medical devices and genetic toxicology for several years,” Dr. Poth said. “Our hope is that someday we can eliminate animal testing entirely.”
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
Commonly Prescribed Painkillers: What Can be Done to Reduce Risk of Obesity and Sleep Deprivation?News
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.READ MORE
New Drug Delivery System Targets Diseases at a Genetic LevelNews
A new drug delivery system that uses a synthetic-biological hybrid nanocapsule could provide a smart technology for targeted treatment of a variety of serious diseases at the genetic level.